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Vertical transMission of HiV
How are countries in sub-Saharan African 
monitoring the impact of programmes to prevent 
vertical transmission of HIV?
Ameena Goga and colleagues describe how five countries in sub-Saharan Africa are monitoring 
the effectiveness of national programmes to prevent vertical transmission of HIV
Vertical transmission of HIV can occur during pregnancy, delivery, or through breast feeding. The main driver of vertical transmission is a high 
maternal viral load.1 Between 2002 and 
2016, low and middle income countries 
(LMICs) in sub-Saharan Africa with high 
HIV prevalence improved their policies 
to prevent vertical transmission of HIV. 
In 2002, national policies recommended 
single dose nevirapine at the onset of 
labour, with limited or no breast feeding. 
By 2016, all Global Plan priority countries 
in sub-Saharan Africa (where 90% of the 
world’s HIV positive pregnant women live) 
had adopted Option B+ with promotion of 
breast feeding.2 Option B+ was a dramatic 
policy change recommending lifelong 
triple antiretroviral therapy (ART) for all 
pregnant and lactating women living with 
HIV. The aim is to protect the child from 
HIV infection, ensure the mother’s future 
health, and prevent horizontal transmis-
sion of HIV.
Monitoring country level effectiveness 
of these policy changes is critical, both 
to ensure they are making a difference 
to people’s lives and to track progress 
t o w a r d s  a c h i e v i n g  g l o b a l  go a l s . 
These goals include the Sustainable 
Development Goal of ending the AIDS 
epidemic by 2030; the Global Plan goals of 
reducing new childhood HIV infections by 
90% and HIV related child deaths by more 
than 50%; and the goal of eliminating 
transmission of HIV between a mother and 
her child so that the transmission rate at 
the end of breast feeding is less than 5% 
and new paediatric HIV infections are ≤50 
per 100 000 live births.2 3 Such monitoring 
is particularly important in LMICs where 
HIV prevalence is high and where health 
systems are often weak or stretched 
beyond capacity.
The  World  Health  Organizat ion 
recommends three methods to measure 
programme effectiveness: statistical 
modelling, surveys or surveillance, and 
analysis of routine programme data (table 
1).4 This paper looks at how five countries 
with high HIV prevalence, prioritised for 
elimination of vertical transmission, have 
translated global guidance on monitoring 
prevention programme effectiveness into 
action.
Our analysis is based on document 
reviews,2 3 peer reviewed publications, 
reports, and a consultation convened 
by the South African Medical Research 
Council in 2016. Representatives from five 
countries (Kenya, Malawi, South Africa, 
Uganda, and Zimbabwe) attended the 
consultation, alongside colleagues from 
key multilateral agencies including the 
Joint United Nations Programme on HIV 
and AIDS (UNAIDS), WHO, the Interagency 
Task Team on the Prevention and 
Treatment of HIV Infection in Pregnant 
Women, Mothers, and their Children, and 
Unicef.
Country approaches and lessons learnt
Statistical modelling
Models are mathematical equations that 
can be used to predict outcomes that are dif-
ficult to measure directly, such as national 
HIV incidence and vertical transmission 
of HIV. Spectrum is a suite of user friendly, 
easily implementable, regularly updated, 
free models that support decision making 
by policy makers (www.avenirhealth.org/
software-spectrum.php). Spectrum consists 
of several software models including the 
Lives Saved Tool, which focuses on child 
survival, and the Aids Impact Model (AIM). 
Other HIV related models, outside of the 
Spectrum suite, include the Asian Epidemic 
model, the Thembisa model (which models 
the South Africa epidemic),5 and the Global 
Burden of Disease (GBD) estimates, drawn 
from vital registration systems. Until now, 
however, GBD data have not been used to 
track effectiveness of prevention of vertical 
transmission.6 Only Spectrum is available 
for use by country teams, who are trained 
regularly, allowing country level tracking 
and intercountry comparison. The Spec-
trum AIM uses HIV sentinel and population 
based surveillance data and programme 
data in demographic models to calculate 
estimates. It can estimate vertical transmis-
sion of HIV, the number of children living 
with HIV, the number of new HIV infec-
tions in children, and HIV related mortal-
ity. Estimates, however, are only as valid as 
the data and assumptions that go into the 
models. Input data are usually drawn from 
prevalence in high risk groups and an esti-
mation of the proportion of the population 
in these groups.6 Spectrum software is used 
by national programmes and UNAIDS to 
prepare estimates for 161 countries, includ-
ing Kenya, Malawi, South Africa, Uganda, 
and Zimbabwe.7
In these countries the Spectrum model 
is used to estimate early (six weeks 
post-delivery) and long term (six weeks 
to 24 months) effectiveness of vertical 
transmission prevention programmes. In 
fact, because no routine cohort monitoring 
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systems exist in LMICs with high HIV 
prevalence, modelling has been the only 
method consistently used to estimate long 
term prevention of vertical transmission 
effectiveness. Until routine data sources 
are more reliable and of better quality, 
modelling is needed to estimate the impact 
of HIV programmes. Modelling is also 
needed to forecast HIV disease burden to 
inform future health needs and service 
provision.7
Surveys or surveillance
Guidance from WHO recommends inter-
mittent immunisation clinic surveys, 
household surveys, or surveillance through 
demographic surveillance sites to measure 
the impact of vertical transmission pro-
grammes in prevention.4 Immunisation 
clinic surveys can be conducted at national 
or subnational level to measure vertical 
transmission of HIV (up to six weeks post-
delivery), number of children living with 
or exposed to HIV, and vertical transmis-
sion of HIV at the end of breast feeding, if 
children can be followed up at later time 
points. Immunisation clinic surveys can 
provide cross sectional and trend data in 
settings with high immunisation coverage 
and allow the collection of coverage and 
outcome data among all children, not only 
children born to mothers who are known 
to have HIV and have interacted with pre-
vention programmes.4 8 9 Immunisation sur-
veys can be expensive, however, especially 
if more staff need to be hired, and they can 
underestimate vertical transmission of 
HIV as recruitment usually occurs after the 
neonatal period, thus excluding early infec-
tions and deaths.
Malawi, South Africa, and Zimbabwe 
have conducted cross sectional surveys 
at immunisation clinics to measure 
prevention of vertical transmission 
effectiveness (table 2), but only Zimbabwe 
and South Africa have generated nationally 
representative estimates. These surveys 
are designed to enrol a clinic attending 
population of mother-infant pairs, 
regardless of HIV status and interaction 
with prevention services (table 1). This 
mitigates selection bias, enrolling mothers 
of unknown HIV status and recently 
diagnosed mothers. Measurements have 
included infant HIV exposure, presumed 
or actual maternal HIV positivity, vertical 
transmission of HIV, uptake of prevention 
interventions, adherence to maternal ART, 
and uptake of routine maternal and child 
healthcare (table 1).
When designing clinic based surveys, 
researchers need to plan for the return of 
the mother’s and infant’s HIV test results 
and need to link participants to appropriate 
care, as it is unethical for these surveys to be 
anonymised or unlinked.
In Malawi, during 2011, a survey was 
conducted in immunisation clinics within 
four of the 28 districts; these four districts 
were purposively selected to reflect regional 
diversity.10 Of the 5068 samples included 
in the analysis from infants less than 3 
Table 1 Strengths and limitations of the methods suggested for prevention of vertical transmission impact monitoring
Method Strengths Limitations
Statistical modelling (Spectrum 
model, for example)
● Easy to implement 
● Estimates for previous years can be updated 
● Provides data for country reports 
● Use of a similar methodology across years enables inter-year comparison 
and tracking of progress 
● Estimates perinatal vertical transmission of HIV, postnatal prevention of 
vertical transmission, child survival by time of infection (perinatally, under 
6 months, 7-12 months, and 12+months after birth), differential vertical 
transmission of HIV by maternal CD4 count, and the effects of incident infec-
tions and new prophylaxis options
● Requires reliable input data. Estimates are, therefore, 
only as valid and up to date as the data they use
Surveys or surveillance
Cross sectional immunisation 
clinic survey follow-up
● Early immunisation uptake 
● Can capture known and unknown HIV exposed infants and HIV unexposed 
infants 
● Can link mothers and babies to HIV related care 
● Can be set up for national, provincial, and district level estimates
● Survival bias—no capture of mothers or babies that 
died 
● Selection bias—does not capture mothers who do 
not seek facility based care 
● Can be expensive to implement if data collectors 
need to be hired and transported to facilities
Health and demographic senti-
nel surveillance
● Allows linking of mother-baby pairs and measurement of long term 
outcome 
● Can obtain final vertical transmission of HIV outcomes and relate it to ART 
and feeding, and to population HIV estimates
● Resource intensive (time, human resources, and cost) 
● Depending on site selection methods, may not 
always be nationally representative
Population based impact 
surveys
● Generalisable to whole population 
● Collect other measures of programme outputs and behaviours 
● Already exist in the form of demographic and health surveys or multiple 
indicator cluster surveys
● Needs large sample size 
● Requires HIV status of mother and infant 
● Expensive to implement 
● Existing surveys have multiple modules and 
outcomes and there are few resources for additional 
questions and blood tests for mother-infant pairs
Use of routine programmatic data
Routine early infant diagnosis 
(EID) and child HIV testing data 
from laboratory
● EID laboratory databases usually exist ● Needs to be coupled with estimated number or per-
centage of children with no HIV test and their outcomes, 
to obtain a national estimate 
● EID data are not always nationally representative and 
exclude HIV positive mothers who do not know they are 
positive 
● Biased from health seeking behaviour 
● Survival bias, as cannot include children who died 
● EID does not tackle final transmission, and cannot 
link mother to child without unique identifiers
Cohort follow-up ● Allows linking of mother-baby pairs and measurement of long term 
outcome 
● Can obtain final vertical transmission of HIV outcomes and relate it to ART 
and feeding
● Attrition to follow-up necessitates assumptions dur-
ing analysis 
● Difficult to trace without unique identifiers 
● Needs functional longitudinal registers 
● Resource intensive (time, human resources, and cost)
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months old, 15.1% (95% confidence 
interval, 14.1 to 16.1) were HIV antibody 
positive. Vertical transmission of HIV was 
8.5% (95% CI, 6.6 to 10.7) with significant 
district level differences.
In South Africa, three nationally and 
provincially representative surveys were 
conducted at immunisation service points 
between 2010 and 2013, during the 
implementation of two different policies to 
prevent vertical transmission of HIV.8 9 The 
surveys demonstrated a reduction in vertical 
transmission of HIV from an estimated 
>25% in the absence of vertical transmission 
prevention interventions to 2.6% in 2012-
13; vertical transmission of HIV risk differed 
by prevention of vertical transmission 
regimen.11 The South Africa surveys were 
expensive to implement; survey data 
collectors were hired because health facility 
staff were overburdened and could not 
incorporate these activities into their daily 
work. In 2012-2014 longitudinal follow-up 
of HIV exposed infants was conducted until 
18 months to assess long term prevention 
of vertical transmission effectiveness. 
Although South Africa implements the 
regular South Africa Demographic and 
Health Survey, by 2016 the survey aims 
were already wide and questionnaires long; 
thus, monitoring the effectiveness of vertical 
transmission prevention using this survey 
has not been feasible.
In Zimbabwe, a nationally representative 
survey to measure effectiveness of vertical 
transmission prevention was conducted 
with 18 month follow-up of mother-infant 
pairs from facility to community. Verbal 
autopsies were conducted to understand 
infant deaths.  Cumulative vertical 
transmission of HIV risk by 18 months was 
7%, and data on the differential vertical 
transmission risk by maternal prevention 
regimen and infant birth weight have been 
published.12 Unlike in South Africa, the 
Zimbabwean survey was implemented by 
health facility staff who received a small 
allowance for their efforts, making the 
Zimbabwean survey less expensive.
Household surveys and population 
based HIV impact assessments provide 
community level data on the HIV epidemic, 
obviating the inherent selection bias in 
facility based surveys (table 2). They have 
great potential for periodically monitoring 
the effectiveness of vertical transmission 
prevention programmes every three to five 
years in settings where adult HIV prevalence 
is greater than 2%. The Ugandan, Malawian, 
and Zimbabwean impact assessments 
included 10 652, 9952, and 9627 children 
aged 0-14, respectively, but analyses have 
not yet focused on the 0-14 year group, and 
have not yet been used to estimate vertical 
transmission of HIV.13-15 The wide paediatric 
age range in current survey designs restricts 
their reliability and validity for monitoring 
prevention programme impact.
Monitoring prevention of vertical 
transmission through longitudinal 
surveillance at demographic surveillance 
sites is theoretically possible. Setting sites 
up is expensive, however, making the use 
of existing sites for vertical transmission 
prevention monitoring easier and less 
expensive. Although demographic 
surveillance sites exist in four of the five 
countries (table 2), as far as we are aware 
these data have only been used to measure 
effectiveness of prevention of vertical 
transmission in Uganda.16 Using data from 
68 000 people from 12 000 households, 
Larsson and colleagues modelled the risk 
of vertical transmission of HIV among 771 
pregnant women in Uganda.16 They also 
modelled the effect of improved prevention 
coverage on vertical transmission of HIV, 
demonstrating that 100% HIV testing 
coverage or 100% ART coverage reduces 
vertical transmission of HIV at birth from 
13.4% to 9.6% and 11% respectively. 
Full (100%) coverage of antenatal clinic 
attendance and HIV testing and ART 
reduces vertical transmission of HIV to 
5.4% at birth.16
Using programme data to monitor prevention 
effectiveness
WHO recommends three sources of routine 
data to monitor the impact of vertical trans-
mission prevention programmes, namely 
routine early infant diagnosis laboratory 
data; retrospective or prospective cohort 
data; and case reporting.4 However, most 
high HIV prevalence settings in LMICs lack 
systems for routine cohort monitoring and 
rely on routine cross sectional data to moni-
tor prevention effectiveness.
Cross sectional routine data
Routine programme data are usually avail-
able at facility, regional, and national lev-
els (table 2), and they are used in Kenya, 
Malawi, Uganda, and South Africa to assess 
pregnant women’s access to HIV testing, 
HIV positive pregnant women’s access to 
ART, HIV exposed infants’ access to HIV 
testing, and infant HIV positivity (table 2). In 
Malawi, data are also collected on ART initi-
ation and retention at 12, 24, and 36 months 
post-delivery. among pregnant women with 
HIV, and vertical transmission of HIV at 6 
weeks, 12 months, and 24 months post-
delivery. The reports are collected quarterly 
and used to identify missed opportunities, 
implement continuous quality improve-
ment, and enhance retention in care.
A case study in Malawi demonstrated 
that involving community leaders, health 
surveillance assistants, and healthcare 
personnel in data review increased 
programme effectiveness.17 In South Africa, 
District Health Information System (DHIS) 
and National Health Laboratory Services 
data are reviewed regularly and reported on 
at least annually.18 19 DHIS data demonstrate 
significant increases in access to maternal 
ART with concomitant decreases in early 
polymerase chain reaction (PCR) positivity 
at six weeks post-delivery over the past five 
years.19 Although routine data are readily 
available, data accuracy is low.20 South 
Africa, Malawi, Uganda, and Kenya also 
use laboratory data to document trends 
in PCR positivity.18 Recent analyses in 
South Africa demonstrate comparability 
between laboratory generated and survey 
generated vertical transmission of HIV 
estimates.21 Laboratory data cannot, 
however, provide information on drivers of 
vertical transmission as laboratory forms do 
not capture maternal risk factors, exposure 
to prevention interventions, or infant 
feeding patterns, and rely on clinicians to 
complete information such as infant age. 
Furthermore, laboratory data need to be 
de-duplicated, as they often contain repeat 
infant HIV tests.22
Cohort monitoring
Routine cohort monitoring facilitates the 
tracking of long term (six weeks to 24 
months) prevention of vertical transmis-
sion outcomes (table 1). Kenya, Malawi, 
and Uganda have piloted cohort monitor-
ing of mothers on ART and HIV exposed 
infants from birth (table 2). Such moni-
toring enhances maternal retention at 3, 
6, and 12 months, as missed opportuni-
ties are recognised easily and corrective 
action can be taken at clinic and commu-
nity levels. In Uganda, the HIV Exposed 
Infants Birth Cohort Analysis monitors HIV 
exposed infants’ service uptake at critical 
time points (6 weeks, 9 and 18 months) and 
outcomes at 9 and 18 months. Over three 
years of implementation of the analysis, the 
proportion of HIV exposed infants retained 
in care at 18 months increased from 83% in 
2012 to 93% in 2014 (personal communi-
cation, Linda Nabitaka, Ministry of Health, 
Kampala, Uganda).
Conclusions
Countries have mainly used modelling with 
Spectrum software, immunisation clinic 
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surveys, and routine cross sectional data 
to monitor vertical transmission of HIV 
prevention programme effectiveness. With 
recent expansion to routine cohort moni-
toring in three countries, however, several 
additional opportunities exist to monitor 
programmes. These include population 
based HIV impact assessments, health and 
demographic sentinel surveillance, demo-
graphic and health surveys, and laboratory 
data. There is a critical need to strengthen 
routine cohort monitoring as this is the 
most sustainable approach to measure long 
term effectiveness of vertical transmission 
prevention programmes.
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